Potential

Gilead’s Breakthrough: FDA Greenlights Lenacapavir Injection, Ushering New Era in HIV Prevention and Investment Potential

FDA approves Gilead HIV prevention injection lenacapavir

Gilead’s Game-Changer in HIV Prevention: What Investors and Advisors Must Know Now In a landmark move that could redefine the trajectory of the global HIV epidemic, the FDA has greenlit Gilead Sciences’ new twice-yearly antiviral … Read more

May Retail Sales and Core Spending Disappoint, Signaling Potential Economic Slowdown Before Crucial Fed Meeting—What Investors Need to Watch

Retail Sales, Core Spending Miss in May, Raising Growth Risks Ahead of Fed Decision

Retail Trade Faces Headwinds While E-Commerce and Food Services Shine: What Investors Must Know Now The latest retail sales data for May paints a nuanced picture that investors can’t afford to overlook. Overall retail trade … Read more